blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3200775

EP3200775 - COMBINATION THERAPIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.09.2020
Database last updated on 13.09.2024
FormerThe patent has been granted
Status updated on  18.10.2019
FormerGrant of patent is intended
Status updated on  16.06.2019
FormerExamination is in progress
Status updated on  26.01.2018
FormerRequest for examination was made
Status updated on  07.07.2017
FormerThe international publication has been made
Status updated on  11.04.2017
Most recent event   Tooltip11.08.2023Lapse of the patent in a contracting state
New state(s): SI		published on 13.09.2023  [2023/37]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2017/32]
Inventor(s)01 / CAO, Zhu, Alexander
Novartis Institutes for Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
02 / RONG, Xianhui
Novartis Institutes for Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
03 / PINZON-ORTIZ, Maria, Consuelo
Novartis Institutes for Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
04 / LONGMIRE, Tyler
Novartis Institutes for Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
05 / LEE, Benjamin, Hyun
Novartis Institutes for Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
 [2017/32]
Representative(s)Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
[2019/47]
Former [2017/32]Truscott, Glyn John
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Application number, filing date15782164.602.10.2015
[2017/32]
WO2015US53799
Priority number, dateUS201462059832P03.10.2014         Original published format: US 201462059832 P
[2017/32]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016054555
Date:07.04.2016
Language:EN
[2016/14]
Type: A2 Application without search report 
No.:EP3200775
Date:09.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 07.04.2016 takes the place of the publication of the European patent application.
[2017/32]
Type: B1 Patent specification 
No.:EP3200775
Date:20.11.2019
Language:EN
[2019/47]
Search report(s)International search report - published on:EP30.06.2016
ClassificationIPC:A61K39/395, A61K31/506, C07K16/28, A61P35/00
[2019/24]
CPC:
C07K16/2818 (EP,KR,US); A61K39/395 (KR); A61K45/06 (EP,CN,KR,US);
A61K39/39558 (US); A61K31/4045 (EP,US); A61K31/427 (EP,US);
A61K31/436 (EP,US); A61K31/444 (EP,US); A61K31/496 (EP,US);
A61K31/506 (EP,CN,KR,US); A61K31/519 (EP,US); A61K31/55 (EP,US);
A61K39/39541 (EP,US); A61K39/3955 (CN); A61K9/0019 (US);
A61K9/0053 (US); A61P35/00 (EP,US); C07K16/2803 (US);
C07K16/2827 (US); C07K16/3015 (US); C07K16/3023 (US);
C07K16/303 (US); C07K16/3038 (US); C07K16/3046 (US);
C07K16/3053 (US); C07K16/3069 (US); G01N33/574 (EP,KR,US);
A61K2039/505 (EP,KR,US); A61K2300/00 (KR); C07K2317/21 (EP,US);
C07K2317/31 (US); C07K2317/52 (US); C07K2317/76 (EP,KR,US) (-)
C-Set:
A61K31/506, A61K2300/00 (US,CN,EP);
A61K39/39541, A61K2300/00 (EP,US);
A61K39/3955, A61K2300/00 (CN)
Former IPC [2017/32]A61K31/00, A61K39/395, A61P35/00, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/32]
Extension statesBA11.04.2017
ME11.04.2017
Validation statesMANot yet paid
TitleGerman:KOMBINATIONSTHERAPIEN[2017/32]
English:COMBINATION THERAPIES[2017/32]
French:POLYTHÉRAPIES[2017/32]
Entry into regional phase11.04.2017National basic fee paid 
11.04.2017Designation fee(s) paid 
11.04.2017Examination fee paid 
Examination procedure11.04.2017Examination requested  [2017/32]
11.04.2017Date on which the examining division has become responsible
21.11.2017Amendment by applicant (claims and/or description)
29.01.2018Despatch of a communication from the examining division (Time limit: M06)
08.08.2018Reply to a communication from the examining division
06.09.2018Despatch of a communication from the examining division (Time limit: M06)
15.03.2019Reply to a communication from the examining division
17.06.2019Communication of intention to grant the patent
15.10.2019Fee for grant paid
15.10.2019Fee for publishing/printing paid
15.10.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19206634.8  / EP3662903
Opposition(s)21.08.2020No opposition filed within time limit [2020/44]
Fees paidRenewal fee
11.10.2017Renewal fee patent year 03
11.10.2018Renewal fee patent year 04
15.10.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.10.2015
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MK20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
[2023/37]
Former [2022/32]HU02.10.2015
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MK20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2022/27]HU02.10.2015
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2021/31]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/51]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/37]AL20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/36]AL20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/35]AL20.11.2019
CZ20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/32]AL20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/26]FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/24]FI20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/23]FI20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
Former [2020/22]FI20.11.2019
LT20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
Former [2020/21]NO20.02.2020
Cited inInternational search[X]US5968511  (AKITA ROBERT [US], et al) [X] 1-5,8,9,22,23,25,51 * the whole document *;
 [X]WO2007113648  (PFIZER PROD INC [US], et al) [X] 1-5,7-12,22,23,25,27,51 * page 67, line 19 *;
 [XI]WO2010051502  (BIOGEN IDEC INC [US], et al) [X] 1-5,7-9,22,23,25,51 * page 72, line 24 - page 73, line 7 * [I] 6,10-21,24,26-30,40,41;
 [A]WO2011011027  (BRISTOL MYERS SQUIBB CO [US], et al) [A] 1-51 * examples 1-7 * * paragraph [0157] *;
 [XD]WO2012022814  (NOVARTIS AG [CH], et al) [XD] 1-5,8,9,22,23,25,51 * the whole document *;
 [XP]WO2015095423  (GENENTECH INC [US], et al) [XP] 1-5,7-12,14,22-30,34,35,49-51 * paragraph [0381] *;
 [XP]WO2015095811  (BOARD INST INC [US], et al) [XP] 1-5,8-12,14,22-30,44-46,49-51 * example 10 * * paragraph [0347] *;
 [XP]WO2015112900  (DANA FARBER CANCER INSTITUE INC [US], et al) [XP] 1-5,8-14,18,22-30,34,35,42,43,49-51 * page 151 *;
 [XP]WO2015117002  (NOVARTIS AG [CH], et al) [XP] 1-5,8-13,20-26,34,35,49-51 * pages 161,162 *;
 [XP]WO2015138920  (NOVARTIS AG [CH], et al) [XP] 1-5,8-13,16,17,22-26,34,35,51 * pages 167,168 *;
 [E]WO2016028672  (MERCK SHARP & DOHME [US], et al) [E] 1-5,8-12,16,17,22-26,51 * page 135, line 22 ** page 162, line 10 *;
 [L]WO2016040880  (NOVARTIS AG [CH], et al) [L] * the whole document *;
 [L]WO2016040892  (NOVARTIS AG [CH], et al) [L] * the whole document *;
 [XI]  - YUAN Z ET AL, "Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-[alpha] leads to synergistic antitumor activity", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 20, no. 1, doi:10.1038/CGT.2012.83, ISSN 0929-1903, (20130101), pages 46 - 56, (20121116), XP008178507 [X] 1-5,7-9,20,22,23,25,51 * abstract * [I] 6,10,15-17,19,21,24,26,31-33

DOI:   http://dx.doi.org/10.1038/cgt.2012.83
 [T]  - NAKAE S ET AL, "Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20060215), vol. 176, no. 4, doi:10.4049/JIMMUNOL.176.4.2238, ISSN 0022-1767, pages 2238 - 2248, XP002752656 [T] * abstract *

DOI:   http://dx.doi.org/10.4049/​jimmunol.176.4.2238
 [A]  - KNIGHTS A J ET AL, "Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 62, no. 2, doi:10.1007/S00262-012-1342-1, ISSN 0340-7004, (20130201), pages 321 - 335, (20120826), XP002752661 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-012-1342-1
 [A]  - R. MOREIRA DA SILVA, "Nivolumab: Anti-PD-1 monoclonal antibody cancer immunotherapy", DRUGS OF THE FUTURE, ES, (20140101), vol. 39, no. 1, doi:10.1358/dof.2014.039.01.2103754, ISSN 0377-8282, pages 15 - 24, XP055199597 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1358/dof.2014.039.01.2103754
 [A]  - MATTHEW VANNEMAN ET AL, "Combining immunotherapy and targeted therapies in cancer treatment", NATURE REVIEWS CANCER, (20120101), vol. 12, no. 4, doi:10.1038/nrc3237, ISSN 1474-175X, pages 237 - 251, XP055045378 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1038/nrc3237
 [A]  - GARRISON K ET AL, "The small molecule TGF-[beta] signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 4, doi:10.1007/S00262-011-1119-Y, ISSN 1432-0851, (20120401), pages 511 - 521, (20111005), XP002752658 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-011-1119-y
 [T]  - ZHUANG J ET AL, "Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis", PHARMACOLOGY RESEARCH & PERSPECTIVES, JOHN WILEY & SONS LTD, GB, vol. 2, no. 6, doi:10.1002/PRP2.81, ISSN 2052-1707, (20141201), Database accession no. E00081, pages 1 - 14, (20140901), XP002752660 [T] * abstract *

DOI:   http://dx.doi.org/10.1002/prp2.81
 [A]  - JOSE LUIS PEREZ-GRACIA ET AL, "Orchestrating immune check-point blockade for cancer immunotherapy in combinations", CURRENT OPINION IN IMMUNOLOGY, (20140401), vol. 27, doi:10.1016/j.coi.2014.01.002, ISSN 0952-7915, pages 89 - 97, XP055200525 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.coi.2014.01.002
 [XI]  - VERBRUGGE INGE ET AL, "The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling", RADIATION RESEARCH, RADIATION RESEARCH SOCIETY, GB, vol. 182, no. 2, doi:10.1667/RR13511.1, ISSN 1938-5404, (20140801), pages 219 - 229, (20140624), XP002745809 [X] 1-5,7-12,22,23,25,27,51 * figure 1C * [I] 6,15,19

DOI:   http://dx.doi.org/10.1667/RR13511.1
 [A]  - Q. JIANG ET AL, "mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment", CANCER RESEARCH, (20110503), vol. 71, no. 12, doi:10.1158/0008-5472.CAN-10-3968, ISSN 0008-5472, pages 4074 - 4084, XP055099556 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-10-3968
 [XI]  - Wang et al, "The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma", (20141001), Cancer Research, URL: http://cancerres.aacrjournals.org/content/74/19_Supplement/5466, (20160414), XP002756552 [X] 1-5,8,9,22,23,25,51 * the whole document * [I] 6,7,10-21,24,26-30,36,37,49,50
 [A]  - Wang et al, "Abstract 2929: The Mdm2 inhibitorNVP-CGM097 enhances the anti-tumor activityof NVP-LDK378 in ALK mutant neuroblastomamodels", (20141001), Cancer Research, URL: http://cancerres.aacrjournals.org/content/74/19_Supplement/2929, (20160414), XP002756553 [A] 1-51 * the whole document *
 [T]  - JIANG X ET AL, "The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 3, doi:10.1158/1078-0432.CCR-12-2731, ISSN 1078-0432, (20130201), pages 598 - 609, (20121024), XP002746139 [T] * abstract *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-2731
 [A]  - ANWESHA DEY ET AL, "Nutlin-3 inhibits the NF[kappa]B Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy", CELL CYCLE, US, (20070901), vol. 6, no. 17, doi:10.4161/cc.6.17.4643, ISSN 1538-4101, pages 2178 - 2185, XP055203309 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.4161/cc.6.17.4643
 [XI]  - Garcia et al, "The Pan-PIM Kinase Inhibitor LGH447 Shows Activity In PIM2-Dependent Multiple Myeloma and In AML Models", (20131115), Blood, URL: http://www.bloodjournal.org/content/122/21/1666, (20160414), XP002756554 [X] 1-5,8,9,22,25,51 * the whole document * [I] 6,7,10-13,23,24,26-30,38,39,49,50
 [A]  - M PINZON-ORTIZ ET AL, "S710: THE COMBINATION OF JAK INHIBITOR RUXOLITINIB, PAN-PIM INHIBITOR LGH447, AND CDK4/6 INHIBITOR LEE011 IN A PRECLINICAL MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASIA", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, IT, (20140601), vol. 99, no. Suppl. 1, ISSN 0390-6078, page 252, XP055171531 [A] 1-51 * the whole document *
 [T]  - CHERVONTSEVA A M ET AL, "Effect of cytarabine on expression of cell adhesion molecules and on endothelium-leukocyte interaction in vitro.", TERAPEVTICHESKII ARKHIV 2006, (2006), vol. 78, no. 7, ISSN 0040-3660, pages 67 - 72, XP008179894 [T] * abstract *
 [X]  - A. J. CHRISTIANSEN ET AL, "Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20110222), vol. 108, no. 10, doi:10.1073/pnas.1011037108, ISSN 0027-8424, pages 4141 - 4146, XP055121803 [X] 1-5,7-9,22,23,25,51 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1011037108
 [XI]  - Woods et al, "Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy", (20141001), Cancer Research, URL: http://cancerres.aacrjournals.org/content/74/19_Supplement/4090.short, (20160414), XP002756556 [X] 1-5,8,9,22,23,25,51 * the whole document * [I] 6,10,15,19,24,26
 [A]  - KIM KIBEM ET AL, "Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. (Includes Supporting Information)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20140812), vol. 111, no. 32, ISSN 1091-6490, pages 11774 - 7, XP002756557 [A] 1-51 * page 11776, column right - page 11777, column left * * figure 1G; table S2 * * page 11779 * * page Suppl. 2 *

DOI:   http://dx.doi.org/10.1073/pnas.1410626111
 [T]  - OKI Y ET AL, "Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.", BLOOD CANCER JOURNAL, (2014), vol. 4, ISSN 2044-5385, pages 1 - 4, XP002756558 [T] * figure 2 *

DOI:   http://dx.doi.org/10.1038/bcj.2014.58
 [A]  - KLEIN JAN M ET AL, "The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.", PLOS ONE, (2013), vol. 8, no. 11, ISSN 1932-6203, pages 1 - 6, XP002756559 [A] 1-51 * abstract *

DOI:   http://dx.doi.org/10.1371/journal.pone.0079502
 [A]  - SONG W ET AL, "HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.", LEUKEMIA JAN 2011, (201101), vol. 25, no. 1, ISSN 1476-5551, pages 161 - 168, XP002756560 [A] 1-51 * abstract *

DOI:   http://dx.doi.org/10.1038/leu.2010.244
 [T]  - Song et al, "3681 Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations", (20091203), 51st ASH Annual Meeting and Exposition, URL: https://ash.confex.com/ash/2009/webprogram/Paper22684.html, (20160414), XP002756561 [T] * abstract *
 [T]  - WOODS DAVID M ET AL, "HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.", CANCER IMMUNOLOGY RESEARCH, (201512), vol. 3, no. 12, ISSN 2326-6074, pages 1375 - 1385, XP002756562 [T] * figure 6A *

DOI:   http://dx.doi.org/10.1158/2326-6066.CIR-15-0077-T
 [A]  - WOODS DAVID M ET AL, "The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.", MELANOMA RESEARCH, (201310), vol. 23, no. 5, ISSN 1473-5636, pages 341 - 348, XP002756563 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1097/CMR.0b013e328364c0ed
 [A]  - Bellucci et al, "JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression", (20131115), Blood, URL: http://www.bloodjournal.org/content/122/21/3472.full.pdf, (20160414), XP002756564 [A] 1-51 * the whole document *
 [X]  - QUINTARELLI CONCETTA ET AL, "Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia", LEUKEMIA RESEARCH, NEW YORK,NY, US, (20131115), vol. 38, no. 2, doi:10.1016/J.LEUKRES.2013.11.006, ISSN 0145-2126, pages 236 - 242, XP028812560 [X] 1-5,7-9,22,24 * figure 3 *

DOI:   http://dx.doi.org/10.1016/j.leukres.2013.11.006
 [T]  - CHRISTIANSSON LISA ET AL, "The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.", MOLECULAR CANCER THERAPEUTICS, (201505), vol. 14, no. 5, ISSN 1538-8514, pages 1181 - 1191, XP002756565 [T] * abstract *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-14-0849
 [XI]  - HU YI ET AL, "Essential role of AKT in tumor cells addicted to FGFR.", ANTI-CANCER DRUGS, (201402), vol. 25, no. 2, ISSN 1473-5741, pages 183 - 188, XP008179886 [X] 1-5,8,9,22,51 * the whole document * [I] 6,7,10,14,15,18,24,26-30,47-50

DOI:   http://dx.doi.org/10.1097/CAD.0000000000000034
 [A]  - J. ACQUAVIVA ET AL, "FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism", MOLECULAR CANCER RESEARCH, (20140701), vol. 12, no. 7, doi:10.1158/1541-7786.MCR-14-0004, ISSN 1541-7786, pages 1042 - 1054, XP055182977 [A] 1-51 * the whole document *

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-14-0004
 [T]  - MITTENDORF ELIZABETH A ET AL, "PD-L1 expression in triple-negative breast cancer.", CANCER IMMUNOLOGY RESEARCH, (201404), vol. 2, no. 4, ISSN 2326-6074, pages 361 - 370, XP002756567 [T] * abstract *

DOI:   http://dx.doi.org/10.1158/2326-6066.CIR-13-0127
 [T]  - GRYGIELEWICZ PAULINA ET AL, "Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells", GASTRIC CANCER, SPRINGER JAPAN, TOKYO, vol. 19, no. 1, doi:10.1007/S10120-014-0444-1, ISSN 1436-3291, (20141119), pages 53 - 62, (20141119), XP035587475 [T] * the whole document *

DOI:   http://dx.doi.org/10.1007/s10120-014-0444-1
by applicantUS2779780
 EP0125023
 EP0171496
 EP0173494
 WO8601533
 EP0184187
 GB2188638
 US4816567
 WO9002809
 EP0388151
 WO9100906
 WO9110741
 WO9117271
 WO9201047
 WO9203918
 WO9203917
 WO9209690
 WO9215679
 WO9218619
 WO9220791
 EP0519596
 WO9301288
 US5208020
 US5223409
 US5225539
 WO9404678
 WO9410202
 US5475092
 WO9630046
 US5585089
 US5585499
 US5624821
 US5648260
 US5693761
 US5693762
 US5811097
 WO9845332
 US5846545
 WO9920758
 WO9940196
 WO9952552
 US6054297
 WO0035436
 US6111090
 WO0103720
 WO0206213
 WO0222577
 EP0666868
 WO02066470
 US6582959
 WO03064383
 WO03076424
 WO03077914
 US2003190317
 US2003203409
 US2003206899
 WO2004005281
 US6689607
 US6703020
 US2004047858
 WO2004060319
 US6780996
 WO2005007190
 WO2005012359
 US6884879
 WO2005044853
 US2005112126
 WO2005055808
 US2005186208
 WO2005113556
 WO2005115451
 WO2005121142
 US2006009360
 US7025962
 US7060269
 WO2006083289
 US7132255
 WO2006121168
 WO2006122806
 WO2007005874
 WO2007004415
 US7169791
 WO2007014011
 WO2007070514
 WO2007084786
 WO2007133822
 EP1866339
 EP1870399
 WO2008016893
 WO2008024725
 EP0920505
 WO2008073687
 WO2009036082
 EP2051990
 WO2009055730
 WO2009085983
 WO2009101611
 EP2099447
 WO2009114335
 WO2009114870
 US7598257
 US7618632
 WO2009141386
 WO2010003118
 WO2010006086
 US2010028330
 WO2010019570
 US2010056576
 WO2010027827
 WO2010026124
 WO2010029082
 WO2010036380
 US2010105667
 WO2010077634
 US7767675
 US7812135
 WO2010125571
 WO2011025927
 WO2011028683
 WO2011051726
 US7943743
 WO2011066342
 US2011150892
 WO2011076786
 EP2344474
 WO2011090754
 US8008449
 US8039479
 WO2011155607
 US2012022814
 US2012039906
 US2012114649
 WO2012079000
 EP2474545
 WO2012177624
 US8354509
 WO2013019906
 US8388967
 WO2013039954
 US8415355
 EP2581113
 WO2013054331
 WO2013079174
 WO2013082366
 EP1947183
 US8501758
 US8546336
 US8552156
 US8552002
 US8586023
 US8591886
 WO2013179174
 WO2013184757
 US8609089
 WO2014008218
 WO2014012479
 WO2014018632
 WO2014022332
 US2014044728
 US2014072566
 US8685980
 WO2014059251
 US8709424
 WO2014072493
 US8735551
 WO2014085318
 US2014271618
 WO2015026684
    - VIGLIETTA, V. ET AL., NEUROTHERAPEUTICS, (2007), vol. 4, pages 666 - 675
    - KORMAN, A. J ET AL., ADV. IMMUNOL., (2007), vol. 90, pages 297 - 339
    - WANG, L. ET AL., J. EXP. MED., (20110307), vol. 208, no. 3, pages 577 - 92
    - LEPENIES, B ET AL., ENDOCRINE, METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, (2008), vol. 8, pages 279 - 288
    - SHARPE, A. H. ET AL., NATURE REV. IMMUNOL., (2002), vol. 2, pages 116 - 126
    - LINDLEY, P. S. ET AL., IMMUNOL. REV., (2009), vol. 229, pages 307 - 321
    - DONG, C. ET AL., IMMUNOLOG. RES., (2003), vol. 28, no. 1, pages 39 - 48
    - GREENWALD, R. J. ET AL., ANN. REV. IMMUNOL., (2005), vol. 23, pages 515 - 548
    - GROSS, J. ET AL., J. IMMUNOL., (1992), vol. 149, pages 380 - 388
    - LINSLEY, P. ET AL., IMMUNITY, (1996), vol. 4, pages 535 - 543
    - COYLE, A. J. ET AL., NATURE IMMUNOL., (2001), vol. 2, no. 3, pages 203 - 209
    - COLLINS, M. ET AL., GENOME BIOL., (2005), vol. 6, pages 223.1 - 223.7
    - KORMAN, A. J. ET AL., ADV. IMMUNOL., (2007), vol. 90, pages 297 - 339
    - OKAZAKI ET AL., CURR OPIN IMMUNOL, (2002), vol. 14, pages 391779 - 82
    - BENNETT ET AL., J. IMMUNOL., (2003), vol. 170, pages 711 - 8
    - AGATA ET AL., INT IMMUNOL., (1996), vol. 8, pages 765 - 72
    - FREEMAN ET AL., J. EXP. MED., (2000), vol. 192, pages 1027 - 34
    - EUR. J. IMMUNOL., (2002), vol. 32, pages 634 - 43
    - DONG ET AL., NAT. MED., (2002), vol. 8, pages 787 - 9
    - ISHIDA, Y ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895
    - BLANK, C. ET AL., IMMUNOL. IMMUNOTHER., (20061229), vol. 56, no. 5, pages 739 - 745
    - DONG ET AL., J. MOL. MED., (2003), vol. 81, pages 281 - 7
    - BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., (2005), vol. 54, pages 307 - 314
    - KONISHI ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 5094 - 100
    - IWAI ET AL., PROC. NAT'L. ACAD. SCI. USA, (2002), vol. 99, pages 12293 - 7
    - BROWN ET AL., J. IMMUNOL., (2003), vol. 170, pages 1257 - 66
    - WANG, C. ET AL., CANCER IMMUNOLOGY RESEARCH, (2014), vol. 2, pages 846 - 856
    - FREDERICK, D.T. ET AL., CLINICAL CANCER RESEARCH, (2013), vol. 19, pages 1225 - 31
    - ALI, K. ET AL., NATURE, (2014), vol. 510, pages 407 - 411
    - HAMID, O. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, (2013), vol. 369, no. 2, pages 134 - 44
    - SHAW ET AL., J CLIN ONCOL., (2009), vol. 27, no. 26, pages 4247 - 4253
    - SASAKI ET AL., EUR J CANCER., (2010), vol. 46, no. 10, pages 1773 - 1780
    - SHAW ET AL., N ENGL J MED., (2013), vol. 368, no. 25, pages 2385 - 2394
    - SOCINSKI ET AL., J CLIN ONCOL., (2012), vol. 30, no. 17, pages 2055 - 2062
    - YANG ET AL., J THORAC ONCOL., (2012), vol. 7, no. 1, pages 90 - 97
    - CHOI ET AL., CANCER RES., (2008), vol. 68, no. 13, pages 4971 - 6
    - HORN ET AL., J CLIN ONCOL., (2009), vol. 27, no. 26, pages 4232 - 5
    - KOIVUNEN ET AL., CLIN CANCER RES., (2008), vol. 14, no. 13, pages 4275 - 83
    - SODA ET AL., NATURE, (2007), vol. 448, no. 7153, pages 561 - 6
    - TAKEUCHI ET AL., CLIN CANCER RES., (2008), vol. 14, no. 20, pages 6618 - 24
    - TAKEUCHI ET AL., CLIN CANCER RES., (2009), vol. 15, no. 9, pages 3143 - 9
    - WONG ET AL., CANCER, (20090415), vol. 115, no. 8, pages 1723 - 33
    - RIKOVA ET AL., CELL, (2007), vol. 131, no. 6, pages 1190 - 203
    - SHINOHARA T ET AL., GENOMICS, (1994), vol. 23, no. 3, pages 704 - 6
    - FINGER LR ET AL., GENE, (1997), vol. 197, no. 1-2, pages 177 - 87
    - TRIEBEL ET AL., J. EXP. MED., (1990), vol. 171, pages 1393 - 1405
    - HASTINGS ET AL., EUR J IMMUNOL., (200909), vol. 39, no. 9, pages 2492 - 501
    - HINODA ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, no. 18, pages 6959 - 6963
    - ZIMMERMANN W ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1987), vol. 84, no. 9, pages 2960 - 2964
    - THOMPSON J. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1989), vol. 158, no. 3, pages 996 - 1004
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 444 - 453
    - E. MEYERS; W. MILLER, CABIOS, (1989), vol. 4, pages 11 - 17
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 10
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - CHOTHIA, C. ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - "Protein Sequence and Structure Analysis of Antibody Variable Domains", Antibody Engineering Lab Manual, SPRINGER-VERLAG
    - AL-LAZIKANI ET AL., JMB, (1997), vol. 273, pages 927 - 948
    - SALEH ET AL., CANCER IMMUNOL. IMMUNOTHER., (1990), vol. 32, pages 180 - 190
    - LOBUGLIO ET AL., HYBRIDOMA, (1986), vol. 5, pages 5117 - 5123
    - FUCHS ET AL., BIOLTECHNOLOGY, (1991), vol. 9, pages 1370 - 1372
    - HAY ET AL., HUM ANTIBOD HYBRIDOMAS, (1992), vol. 3, pages 81 - 85
    - HUSE ET AL., SCIENCE, (1989), vol. 246, pages 1275 - 1281
    - GRIFFTHS ET AL., EMBO J, (1993), vol. 12, pages 725 - 734
    - HAWKINS ET AL., JMOL BIOL, (1992), vol. 226, pages 889 - 896
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - GRAM ET AL., PNAS, (1992), vol. 89, pages 3576 - 3580
    - GARRAD ET AL., BIOLTECHNOLOGY, (1991), vol. 9, pages 1373 - 1377
    - HOOGENBOOM ET AL., NUC ACID RES, (1991), vol. 19, pages 4133 - 4137
    - BARBAS ET AL., PNAS, (1991), vol. 88, pages 7978 - 7982
    - LONBERG, N. ET AL., NATURE, (1994), vol. 368, pages 856 - 859
    - GREEN, L.L. ET AL., NATURE GENET., (1994), vol. 7, pages 13 - 21
    - MORRISON, S.L ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 81, pages 6851 - 6855
    - BRUGGEMAN ET AL., YEAR IMMUNOL, (1993), vol. 7, pages 33 - 40
    - TUAILLON ET AL., PNAS, (1993), vol. 90, pages 3720 - 3724
    - BRUGGEMAN ET AL., EUR J IMMUNOL, (1991), vol. 21, pages 1323 - 1326
    - BETTER ET AL., SCIENCE, (1988), vol. 240, pages 1041 - 1043
    - LIU ET AL., PNAS, (1987), vol. 84, pages 3439 - 3443
    - LIU ET AL., J. IMMUNOL., (1987), vol. 139, pages 3521 - 3526
    - SUN ET AL., PNAS, (1987), vol. 84, pages 214 - 218
    - NISHIMURA ET AL., CANC. RES., (1987), vol. 47, pages 999 - 1005
    - WOOD ET AL., NATURE, (1985), vol. 314, pages 446 - 449
    - SHAW ET AL., J. NATL CANCER INST., (1988), vol. 80, pages 1553 - 1559
    - MORRISON, S. L., SCIENCE, (1985), vol. 229, pages 1202 - 1207
    - OI ET AL., BIOTECHNIQUES, (1986), vol. 4, page 214
    - JONES ET AL., NATURE, (1986), vol. 321, pages 552 - 525
    - VERHOEYAN ET AL., SCIENCE, (1988), vol. 239, page 1534
    - BEIDLER ET AL., J. IMMUNOL., (1988), vol. 141, pages 4053 - 4060
    - COLCHER, D. ET AL., ANN N Y ACAD SCI, (1999), vol. 880, pages 263 - 80
    - REITER, Y., CLIN CANCER RES, (1996), vol. 2, pages 245 - 52
    - WOO ET AL., CANCER RES., (2012), vol. 72, no. 4, pages 917 - 27
    - MARKEL ET AL., J IMMUNOL., (20020315), vol. 168, no. 6, pages 2803 - 10
    - MARKEL ET AL., J IMMUNOL., (20061101), vol. 177, no. 9, pages 6062 - 71
    - MARKEL ET AL., IMMUNOLOGY, (200902), vol. 126, no. 2, pages 186 - 200
    - MARKEL ET AL., CANCER IMMUNOL IMMUNOTHER., (201002), vol. 59, no. 2, pages 215 - 30
    - ORTENBERG ET AL., MOL CANCER THER., (201206), vol. 11, no. 6, pages 1300 - 10
    - STERN ET AL., J IMMUNOL., (20050601), vol. 174, no. 11, pages 6692 - 701
    - ZHENG ET AL., PLOS ONE, (20100902), vol. 5, no. 9, page E12529
    - JOHN LB ET AL., CLIN. CANCER RES., (2013), vol. 19, no. 20, pages 5636 - 46
    - KEHRL, J. ET AL., J. EXP. MED., (1986), vol. 163, pages 1037 - 1050
    - HOWARD, M; O'GARRA, A., IMMUNOLOGY TODAY, (1992), vol. 13, pages 198 - 200
    - HAHNE, M. ET AL., SCIENCE, (1996), vol. 274, pages 1363 - 1365
    - RIDGE, J. ET AL., NATURE, (1998), vol. 393, pages 474 - 478
    - ITO, N. ET AL., IMMUNOBIOLOGY, (2000), vol. 201, no. 5, pages 527 - 40
    - WEINBERG, A. ET AL., IMMUNOL, (2000), vol. 164, pages 2160 - 2169
    - MELERO, I. ET AL., NATURE MEDICINE, (1997), vol. 3, pages 682 - 685
    - HUTLOFF, A. ET AL., NATURE, (1999), vol. 397, pages 262 - 266
    - HOLLIGER, PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - POLJAK, STRUCTURE, (1994), vol. 2, pages 1121 - 1123
    - HE ET AL., J. IMMUNOL., (2004), vol. 173, pages 4919 - 28
    - "Development of Cancer Vaccines", ROSENBERG, S., ASCO Educational Book Spring, pages 60 - 62
    - LOGOTHETIS, C., ASCO Educational Book S, (2000), pages 300 - 302
    - KHAYAT, D, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 414 - 428
    - FOON, K., ASCO Educational Book Spring, (2000), pages 730 - 738
    - RESTIFO, N; SZNOL, M., Cancer Vaccines, pages 3023 - 3043
    - DRANOFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1993), vol. 90, pages 3539 - 43
    - KIM, N ET AL., SCIENCE, (1994), vol. 266, pages 2011 - 2013
    - SUOT, R; SRIVASTAVA, P, SCIENCE, (1995), vol. 269, pages 1585 - 1588
    - TAMURA, Y. ET AL., SCIENCE, (1997), vol. 278, pages 117 - 120
    - NESTLE, F. ET AL., NATURE MEDICINE, (1998), vol. 4, pages 328 - 332
    - KUGLER, A ET AL., NATURE MEDICINE, (2000), vol. 6, pages 332 - 336
    - HANNE ET AL., "AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer", N ENGL J MED, (2015), vol. 372, pages 1689 - 99
    - SEQUIST ET AL., "Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer", J MED, (2015), vol. 372, pages 1700 - 9
    - SAKAGAMI ET AL., "ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations", AACR; CANCER RES, (2014), vol. 74, page 1728
    - THERASSE ET AL., "New Guidelines to Evaluate the Response to Treatment in Solid Tumors", JOURNAL OF NATIONAL CANCER INSTITUTE, (2000), vol. 92, pages 205 - 16
    - EISENHAUER ET AL., EUROPEAN JOURNAL OF CANCER, (2009), vol. 45, pages 228 - 247
    - Remington's Pharmaceutical Sciences, MACK PRINTING COMPANY, (1990), pages 1289 - 1329
    - DONG ET AL., NAT MED, (2002), vol. 8, pages 787 - 9
    - DONG ET AL., J MOL MED, (2003), vol. 81, pages 281 - 7
    - BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER, (2005), vol. 54, pages 307 - 314
    - IWAI ET AL., INT. IMMUNOL., (2005), vol. 17, pages 133 - 144
    - MOKYR, M. ET AL., CANCER RESEARCH, (1998), vol. 58, pages 5301 - 5304
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - POPKOV, JOURNAL OF IMMUNOLOGICAL METHODS, (2004), vol. 288, pages 149 - 164
    - LI ET AL., BIOPOLYMERS, (2007), vol. 87, pages 225 - 230
    - LIU ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2007), vol. 17, pages 617 - 620
    - COOK, R., J MANAG CARE PHARM, (2008), vol. 14, no. 7, pages 19 - 25
    - HALLETT, WHD ET AL., J OF AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION, (2011), vol. 17, no. 8, pages 1133 - 145
    - YI, Q, CANCER J., (2009), vol. 15, no. 6, pages 502 - 10
    - RINI, B.I. ET AL., J. CLIN. ONCOL., (2010), vol. 28, no. 13, pages 2137 - 2143
    - PAL. S.K ET AL., CLIN. ADVANCES IN HEMATOLOGY & ONCOLOGY, (2014), vol. 12, no. 2, pages 90 - 99
    - HUDES, G ET AL., N. ENGL. J. MED, (2007), vol. 356, no. 22, pages 2271 - 2281
    - MOTZER, R.J. ET AL., LANCET, (2008), vol. 372, pages 449 - 456
    - PENG ET AL., NATURE BIOTECHNOLOGY, (2011), vol. 29, pages 886 - 891
    - SEAN ET AL., SCIENCE, (2011), vol. 332, no. 6030, pages 687 - 696
    - FREY; DUECK, SCIENCE, (2007), pages 972 - 976
 WO1986US02269
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.